Literature DB >> 20485897

Normocalcemic primary hyperparathyroidism.

John P Bilezikian1, Shonni J Silverberg.   

Abstract

Primary hyperparathyroidism is a common disorder of mineral metabolism characterized by incompletely regulated, excessive secretion of parathyroid hormone from one or more of the parathyroid glands. The historical view of this disease describes two distinct entities marked by two eras. When primary hyperparathyroidism was first discovered about 80 years ago, it was always symptomatic with kidney stones, bone disease and marked hypercalcemia. With the advent of the multichannel autoanalyzer about 40 years ago, the clinical phenotype changed to a disorder characterized by mild hypercalcemia and the absence of classical other features of the disease. We may now be entering a 3rd era in the history of this disease in which patients are being discovered with normal total and ionized serum calcium concentrations but with parathyroid hormone levels that are consistently elevated. In this article, we describe this new entity, normocalcemic primary hyperparathyroidism, a forme fruste of the disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20485897      PMCID: PMC3127400          DOI: 10.1590/s0004-27302010000200004

Source DB:  PubMed          Journal:  Arq Bras Endocrinol Metabol        ISSN: 0004-2730


  17 in total

Review 1.  Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century.

Authors:  John P Bilezikian; John T Potts; Ghada El-Hajj Fuleihan; Michael Kleerekoper; Robert Neer; Munro Peacock; Jonas Rastad; Shonni J Silverberg; Robert Udelsman; Samuel A Wells
Journal:  J Bone Miner Res       Date:  2002-11       Impact factor: 6.741

2.  Characterization of normocalcemic primary hyperparathyroidism.

Authors:  Karen M Tordjman; Yona Greenman; Etty Osher; Galina Shenkerman; Naftali Stern
Journal:  Am J Med       Date:  2004-12-01       Impact factor: 4.965

Review 3.  The Vitamin D requirement in health and disease.

Authors:  Robert P Heaney
Journal:  J Steroid Biochem Mol Biol       Date:  2005-07-18       Impact factor: 4.292

Review 4.  Vitamin D deficiency.

Authors:  Michael F Holick
Journal:  N Engl J Med       Date:  2007-07-19       Impact factor: 91.245

5.  A non-(1-84) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in uremic samples.

Authors:  R Lepage; L Roy; J H Brossard; L Rousseau; C Dorais; C Lazure; P D'Amour
Journal:  Clin Chem       Date:  1998-04       Impact factor: 8.327

6.  Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1-84: implications for improvement of accurate assessment of parathyroid function.

Authors:  P Gao; S Scheibel; P D'Amour; M R John; S D Rao; H Schmidt-Gayk; T L Cantor
Journal:  J Bone Miner Res       Date:  2001-04       Impact factor: 6.741

7.  Primary hyperparathyroidism revisited in menopausal women with serum calcium in the upper normal range at population-based screening 8 years ago.

Authors:  Ewa Lundgren; Emil G Hagström; Jonas Lundin; Kajsa Winnerbäck; Johanna Roos; Sverker Ljunghall; Jonas Rastad
Journal:  World J Surg       Date:  2002-06-06       Impact factor: 3.352

8.  Normocalcemic primary hyperparathyroidism: evidence for a generalized target-tissue resistance to parathyroid hormone.

Authors:  Gérard Maruani; Alexandre Hertig; Michel Paillard; Pascal Houillier
Journal:  J Clin Endocrinol Metab       Date:  2003-10       Impact factor: 5.958

9.  Clinical utility of an immunoradiometric assay for parathyroid hormone (1-84) in primary hyperparathyroidism.

Authors:  Shonni J Silverberg; Ping Gao; Ijeoma Brown; Paul LoGerfo; Tom L Cantor; John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2003-10       Impact factor: 5.958

10.  Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype.

Authors:  H Lowe; D J McMahon; M R Rubin; J P Bilezikian; S J Silverberg
Journal:  J Clin Endocrinol Metab       Date:  2007-05-29       Impact factor: 5.958

View more
  24 in total

Review 1.  [Primary hyperparathyroidism - current diagnosis and therapy].

Authors:  Kristina Pluemacher; Heide Siggelkow
Journal:  Med Klin (Munich)       Date:  2010-08

2.  Surgical management of normocalcemic primary hyperparathyroidism.

Authors:  Thomas J Wade; Tina W F Yen; Amanda L Amin; Tracy S Wang
Journal:  World J Surg       Date:  2012-04       Impact factor: 3.352

Review 3.  Mild primary hyperparathyroidism: a literature review.

Authors:  Megan K Applewhite; David F Schneider
Journal:  Oncologist       Date:  2014-07-25

4.  Diagnosis and clinico-radiological presentation in an aggressive maxillary brown tumour.

Authors:  Abhishek Ranjan Pati; Vijayalakshmi Kr; Chandravir Singh
Journal:  J Clin Diagn Res       Date:  2014-05-15

Review 5.  Normocalcemic primary hyperparathyroidism.

Authors:  Natalie E Cusano; Shonni J Silverberg; John P Bilezikian
Journal:  J Clin Densitom       Date:  2013 Jan-Mar       Impact factor: 2.617

6.  Effects of alendronate and vitamin D in patients with normocalcemic primary hyperparathyroidism.

Authors:  R Cesareo; E Di Stasio; F Vescini; G Campagna; R Cianni; V Pasqualini; F Romitelli; F Grimaldi; S Manfrini; A Palermo
Journal:  Osteoporos Int       Date:  2014-12-19       Impact factor: 4.507

7.  Normocalcemic hyperparathyroidism is associated with complications similar to those of hypercalcemic hyperparathyroidism.

Authors:  Mazhar Müslüm Tuna; Mustafa Çalışkan; Mustafa Ünal; Taner Demirci; Berçem Ayçiçek Doğan; Kerim Küçükler; Mustafa Özbek; Dilek Berker; Tuncay Delibaşı; Serdar Güler
Journal:  J Bone Miner Metab       Date:  2015-06-09       Impact factor: 2.626

Review 8.  Pediatric hyperparathyroidism: review and imaging update.

Authors:  Hedieh Khalatbari; Safia H E Cheeney; Scott C Manning; Marguerite T Parisi
Journal:  Pediatr Radiol       Date:  2021-04-27

Review 9.  Primary hyperparathyroidism in pregnancy.

Authors:  Gonzalo Diaz-Soto; Agnès Linglart; Marie-Victoire Sénat; Peter Kamenicky; Philippe Chanson
Journal:  Endocrine       Date:  2013-05-14       Impact factor: 3.633

Review 10.  Osteoporosis in men: recent progress.

Authors:  Robert A Adler
Journal:  Endocrine       Date:  2013-01-25       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.